<DrugInformationSummary id="CDR0000809173"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about nivolumab and relatlimab-rmbw
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-relatlimab-rmbw">Nivolumab and Relatlimab-rmbw</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000809169">nivolumab/relatlimab-rmbw</TerminologyLink><GlossaryLink ref="CDR0000809171">nivolumab and relatlimab</GlossaryLink><USBrandNames><USBrandName>Opdualag</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>nih-VOL-yoo-mab … reh-LAT-lih-mab</TermPronunciation><MediaLink ref="CDR0000809834" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000809835" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Nivolumab and Relatlimab-rmbw</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Nivolumab and relatlimab-rmbw 
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">Melanoma</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> or cannot be removed by <GlossaryTermRef href="CDR0000045570" dictionary="Cancer.gov" audience="Patient">surgery</GlossaryTermRef>. It is used in adults and children aged 12 years and older.</ListItem>
   </ItemizedList>
  <Para id="_4">Nivolumab and relatlimab-rmbw is a combination form of <GlossaryTermRef href="CDR0000767747" dictionary="Cancer.gov" audience="Patient">nivolumab</GlossaryTermRef> and relatlimab. This form may work better than either drug  alone. For more information about nivolumab that may apply to this combination drug, see the Drug Information Summary for <DrugRef href="CDR0000767749" url="/about-cancer/treatment/drugs/nivolumab">Nivolumab</DrugRef>.</Para><Para id="_5">Nivolumab and relatlimab-rmbw 
         is also being studied in the treatment of other types of
         <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.</Para>
 </Section><Section id="_About"><Title>More About Nivolumab and Relatlimab-rmbw</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/809169">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.71">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a622037.html">Nivolumab and Relatlimab-rmbw</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.72"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.73">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-myocarditis-cause">Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-opdualag-melanoma-lag-3">Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2021/melanoma-nivolumab-relatlimab-immunotherapy">Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C186440">Find Clinical Trials for Nivolumab/relatlimab-rmbw</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2022-04-14</DateFirstPublished><DateLastModified>2022-12-22</DateLastModified></DrugInformationSummary>
